Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Natalizumab |
Synonyms | |
Therapy Description |
Tysabri (natalizumab) is a monoclonal antibody that binds to alpha 4 integrin and inhibits adhesion, resulting in immune modulation and anti-tumor activities (PMID: 23319569). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Natalizumab | Tysabri | Anti-VLA4 | Tysabri (natalizumab) is a monoclonal antibody that binds to alpha 4 integrin and inhibits adhesion, resulting in immune modulation and anti-tumor activities (PMID: 23319569). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03811886 | Phase Ib/II | Natalizumab | Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma | Recruiting | USA | 0 |